Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

Thumbnail
Date
2004-04
ICR Author
Workman, Paul
Author
Workman, P
Type
Journal Article
Metadata
Show full item record
Abstract
There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)-Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.
URI
https://repository.icr.ac.uk/handle/internal/1919
DOI
https://doi.org/10.1042/bst0320393
Collections
  • Other ICR Research
Subject
Animals
Mice, Knockout
Humans
Mice
Neoplasms
Disease Models, Animal
Disease Progression
Protein Isoforms
Antineoplastic Agents
Enzyme Inhibitors
Genome
Models, Chemical
Phosphatidylinositol 3-Kinases
Language
eng
License start date
2004-04
Citation
Biochemical Society transactions, 2004, 32 (Pt 2), pp. 393 - 396

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.